Expand ALT Menu
ALT MENU

ALT Latest Press Releases

-- August 12, 2026 --

Altimmune Announces Second Quarter 2026 Financial Results and Business Update Globe Newswire 7:30 AM

-- August 5, 2026 --

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 Globe Newswire 8:00 AM

-- August 3, 2026 --

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH Globe Newswire 8:00 AM

-- July 28, 2026 --

Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Globe Newswire 7:00 AM

-- May 28, 2026 --

Pemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48-Week IMPACT Phase 2b Data Presented at EASL 2026 Globe Newswire 11:00 AM

-- May 27, 2026 --

Altimmune to Participate in Upcoming Investor Conferences Globe Newswire 8:30 AM
New IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026 Globe Newswire 8:00 AM

-- May 13, 2026 --

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities Globe Newswire 8:30 AM
Altimmune Announces First Quarter 2026 Financial Results and Business Update Globe Newswire 7:30 AM
Altimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026 Globe Newswire 7:15 AM

-- May 6, 2026 --

Altimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026 Globe Newswire 7:30 AM

-- April 27, 2026 --

Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities Globe Newswire 7:00 AM

-- April 22, 2026 --

Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities Globe Newswire 11:25 PM
Altimmune Announces Proposed Underwritten Public Offering of Securities Globe Newswire 4:19 PM
Market Data Delayed 15 Minutes